Loading...
Loading...
Found 1,747 Skills
Write publication-ready ML/AI papers for NeurIPS, ICML, ICLR, ACL, AAAI, COLM. Use when drafting papers from research repos, conducting literature reviews, finding related work, verifying citations, or preparing camera-ready submissions. Includes LaTeX templates, citation verification workflows, and paper discovery/evaluation criteria.
A pattern for generating higher-quality output by iterating against explicit scoring criteria. Use for headlines, CTAs, landing page copy, social content, ad copy — anything where quality matters. Generate → Evaluate → Diagnose → Improve → Repeat.
Use when asked to "thinking in bets", "make decisions under uncertainty", "think probabilistically", "avoid resulting", "separate decision quality from outcomes", or "reduce bias in decisions". Helps make explicit bets and evaluate decisions on process, not results. The Thinking in Bets framework (from Annie Duke) applies poker strategy to business and life decisions.
Design experiment plans with progressive stages — initial implementation, baseline tuning, creative research, and ablation studies. Plan baselines, datasets, hyperparameter sweeps, and evaluation metrics. Use when planning experiments for a research paper.
Write ML experiment code with iterative improvement. Generate training/evaluation pipelines, debug errors, and optimize results through code reflection. Use when implementing experiments for a research paper.
Post-pipeline retrospective — parse logs, score process quality, find waste patterns, suggest skill/script patches. Use after pipeline completes or when user says "retro", "evaluate pipeline", "what went wrong", "pipeline review", "check pipeline logs".
IMPERSONATE steipete (steipete - Peter Steinberger) and coach the user directly. Use steipete's voice, philosophy, and actual project patterns to evaluate ideas, give feedback, and guide decisions. Based on his 168 GitHub repos and blog posts. When user describes their idea/project/decision, respond AS steipete - challenge, question, approve, or reject.
Comprehensive patient stratification for precision medicine by integrating genomic, clinical, and therapeutic data. Given a disease/condition, genomic data (germline variants, somatic mutations, expression), and optional clinical parameters, performs multi-phase analysis across 9 phases covering disease disambiguation, genetic risk assessment, disease-specific molecular stratification, pharmacogenomic profiling, comorbidity/DDI risk, pathway analysis, clinical evidence and guideline mapping, clinical trial matching, and integrated outcome prediction. Generates a quantitative Precision Medicine Risk Score (0-100) with risk tier assignment (Low/Intermediate/High/Very High), treatment algorithm (1st/2nd/3rd line), pharmacogenomic guidance, clinical trial matches, and monitoring plan. Use when clinicians ask about patient risk stratification, treatment selection, prognosis prediction, or personalized therapeutic strategy across cancer, metabolic, cardiovascular, neurological, or rare diseases.
Comprehensive computational validation of drug targets for early-stage drug discovery. Evaluates targets across 10 dimensions (disambiguation, disease association, druggability, chemical matter, clinical precedent, safety, pathway context, validation evidence, structural insights, validation roadmap) using 60+ ToolUniverse tools. Produces a quantitative Target Validation Score (0-100) with GO/NO-GO recommendation. Use when users ask about target validation, druggability assessment, target prioritization, or "is X a good drug target for Y?"
Predict patient response to immune checkpoint inhibitors (ICIs) using multi-biomarker integration. Given a cancer type, somatic mutations, and optional biomarkers (TMB, PD-L1, MSI status), performs systematic analysis across 11 phases covering TMB classification, neoantigen burden estimation, MSI/MMR assessment, PD-L1 evaluation, immune microenvironment profiling, mutation-based resistance/sensitivity prediction, clinical evidence retrieval, and multi-biomarker score integration. Generates a quantitative ICI Response Score (0-100), response likelihood tier, specific ICI drug recommendations with evidence, resistance risk factors, and a monitoring plan. Use when oncologists ask about immunotherapy eligibility, checkpoint inhibitor selection, or biomarker-guided ICI treatment decisions.
Transform GWAS signals into actionable drug targets and repurposing opportunities. Performs locus-to-gene mapping, target druggability assessment, existing drug identification, safety profile evaluation, and clinical trial matching. Use when discovering drug targets from GWAS data, finding drug repurposing opportunities from genetic associations, or translating GWAS findings into therapeutic leads.
Evaluate product bets and shape pitches using Shape Up's appetite model and Bezos's Type 1/Type 2 decision framework. Use when asked to assess a product bet, evaluate initiative risk, decide resource allocation, or shape a pitch for a new feature or project.